Biotech Investor James Topper Reports a $12 Million $MBX Buy

Every day, we sift through the filings to spot where the real conviction lies – cutting through the noise to highlight the most meaningful insider moves.

Here's what stood out today:

📌 MBX Biosciences $MBX – Director James Topper filed a Form 4 for $11,999,988.

A specialist biotech investor writing a near-$12 million check is some serious conviction in an emerging endocrine play.

Biotech is one of those spaces where following the experts pays off more often than not. 

Here’s The Hot Corner, with data from September 30, 2025:

xxx

Click the table to enlarge it.

📌 United States Antimony $UAMY – Chairman and CEO Gary Evans filed a Form 4 for $613,200.
 
This is a clean open-market buy in a tiny industrial metals producer. It’s quiet but notable as the entire metals and minerals space begins to catch a bid.